1046 related articles for article (PubMed ID: 22831853)
1. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
[TBL] [Abstract][Full Text] [Related]
5. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
Nitti VW; Rosenberg S; Mitcheson DH; He W; Fakhoury A; Martin NE
J Urol; 2013 Oct; 190(4):1320-7. PubMed ID: 23727415
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
[TBL] [Abstract][Full Text] [Related]
7. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.
Oelke M; Giuliano F; Mirone V; Xu L; Cox D; Viktrup L
Eur Urol; 2012 May; 61(5):917-25. PubMed ID: 22297243
[TBL] [Abstract][Full Text] [Related]
9. Re: solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
Wein AJ
J Urol; 2014 Mar; 191(3):739. PubMed ID: 24522051
[No Abstract] [Full Text] [Related]
10. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
[TBL] [Abstract][Full Text] [Related]
11. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
13. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
[TBL] [Abstract][Full Text] [Related]
14. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study.
Yamaguchi O; Kakizaki H; Homma Y; Takeda M; Nishizawa O; Gotoh M; Yokoyama O; Seki N; Yoshida M;
Urology; 2011 Jul; 78(1):126-33. PubMed ID: 21601248
[TBL] [Abstract][Full Text] [Related]
15. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW
Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356
[TBL] [Abstract][Full Text] [Related]
17. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gacci M; Vittori G; Tosi N; Siena G; Rossetti MA; Lapini A; Vignozzi L; Serni S; Maggi M; Carini M
J Sex Med; 2012 Jun; 9(6):1624-33. PubMed ID: 22510238
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
[TBL] [Abstract][Full Text] [Related]
20. [Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe].
Chapple ChR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernandez Fernandez E
Urologiia; 2012; (5):38-42, 44-5. PubMed ID: 23342615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
